The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The current role of autoSCT in HL & how this may evolve with the advent of novel therapeutic options
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, comments on the current role of autologous stem cell transplantation (autoSCT) in Hodgkin lymphoma (HL), emphasizing that it is the only potentially curative option for patients with relapsed/refractory (R/R) disease. Dr Desai notes that recent trials have shown improved outcomes with the incorporation of checkpoint inhibitors or PD-1 inhibitors into salvage regimens prior to transplant, raising questions about whether autoSCT is necessary for every patient. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So currently for relapsed refractory classical Hodgkin lymphoma, autologous stem cell transplant is the only potentially curative option in the current treatment paradigm. This has been true for the last several, last seven decades and in front line autologous stem cell transplant has no role. So we transplant patients or do autologous stem cell transplant only for relapsed/refractory disease...
So currently for relapsed refractory classical Hodgkin lymphoma, autologous stem cell transplant is the only potentially curative option in the current treatment paradigm. This has been true for the last several, last seven decades and in front line autologous stem cell transplant has no role. So we transplant patients or do autologous stem cell transplant only for relapsed/refractory disease. Recently there have been many trials that have shown great response and survival with incorporation of checkpoint inhibitors or PD-1 blockers with salvage regimens before autologous stem cell transplant and that has improved outcomes. So that has raised question of whether we need autologous stem cell transplant in every patient with relapsed or refractory classic Hodgkin lymphoma. And that is being studied in a clinical trial right now. But in standard of care, in the current treatment paradigm, every patient who relapses after frontline treatment, if they can go for autologous stem cell transplant, they are treated with that intent for salvage. They are given salvage therapy, which is a multi-agent chemotherapy with or without PD-1 blocker or with or without brentuximab vedotin, and then if they respond completely, they go for autologous stem cell transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Onclive: Honoraria; CurioScience: Honoraria; Merck: Research Funding; Beigene: Research Funding.
